RAMP3
ENSG00000122679
Target class
Unclassified protein
Chromosome
7
Approved drugs
1
Clinical candidates (approved and in development)
1
- Approved drugs
- 1
- Clinical candidates (approved and in development)
- 1
- Chemical probe available
- No
- Target name
- RAMP3
- Gene name
- Receptor activity modifying protein 3
- Gene symbol
- RAMP3
- Protein name
- Receptor activity-modifying protein 3 (Calcitonin-receptor-like receptor activity-modifying protein 3) (CRLR activity-modifying protein 3)
- Gene biotype
- Protein coding
- Gene family
- Receptor (G protein-coupled) activity modifying proteins
- Target class
- Unclassified protein
- Target type
- Human gene
- Tissues expressed in
- 51
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 220.44
- Tissue specificity (Gini)
- 0.506
- Tissue specificity (tau)
- 0.841
- KEGG gene identifiers
- hsa:10268
- Protein interaction confidence
- 0.910733
- Protein interaction partners
- 15
- R-HSA-418555
- R-HSA-419812
- End position
- 45188665
- Start position
- 45157648
- Chromosome
- 7
- Strand
- Forward
- Cell membrane
- Single-pass type I membrane protein . Membrane
- Single-pass type I membrane protein . Note=Moves from intracellular puncta to the plasma membrane in a RAMP3-dependent manner.
- Plasma membrane
- PubMed 23674134
- PubMed 32296767
- Tissue specificity (tau)
- 0.840639
- Expression inequality (Gini)
- 0.50581
Expression in transcripts per million
- Lung
- 220.44
- Thyroid
- 137.33
- Adipose - Subcutaneous
- 126.28
- Brain - Spinal cord (cervical c-1)
- 115.11
- Breast - Mammary Tissue
- 100.52
Expression in transcripts per million
- Lung220.44
- Thyroid137.33
- Adipose - Subcutaneous126.28
- Brain - Spinal cord (cervical c-1)115.11
- Breast - Mammary Tissue100.52
- Adipose - Visceral (Omentum)85.04
- Kidney - Medulla76.78
- Artery - Coronary67.75
- Kidney - Cortex65.93
- Nerve - Tibial59.05
- Uterus57.23
- Cervix - Endocervix56.59
- Esophagus - Gastroesophageal Junction52.48
- Esophagus - Muscularis48.59
- Vagina47.14
- Prostate46.99
- Fallopian Tube46.83
- Heart - Atrial Appendage40.96
- Bladder40.58
- Small Intestine - Terminal Ileum38.78
- Adrenal Gland36.13
- Heart - Left Ventricle35.31
- Cervix - Ectocervix33.1
- Skin - Sun Exposed (Lower leg)30.46
- Colon - Sigmoid30.14
And 29 more, listed on the interactive page.
- GO:0001921
- GO:0006816
- GO:0007189
- GO:0010628
- GO:0015031
- GO:0031623
- GO:0050850
- GO:0051897
- GO:0070374
- GO:0072659
- GO:0097647
- GO:0141163
- GO:0150061
- GO:1903078
- GO:1904645
- GO:1990410
- GO:0005764
- GO:0005886
- GO:0009986
- GO:0016020
- GO:0043235
- GO:0150058
- GO:1903143
- GO:0001540
- GO:0001605
- GO:0005515
- GO:0015026
- GO:0030545
- GO:0097643
Related records
Trials (132)
- A Dose Selection Study of Oral Recombinant Salmon Calcitonin (rsCT) in Normal, Healthy, Postmenopausal Women
- A Fully Automated Lyumjev and Pramlintide Delivery System for Adults With Type 1 Diabetes
- A Fully-closed Loop, Pramlintide and Insulin, Artificial Pancreas Clinical Trial for Adults With Type 1 Diabetes
- A Pilot Study of Continuous Subcutaneous Pramlintide Infusion Therapy in Patients With Type 1 Diabetes
- A Research Study Looking at How a Single Dose of the Medicine Cagrilintide Works in Participants With Reduced Liver Function and in Healthy Participants With Normal Liver Function and How Cagrilintide is Absorbed and Used by the Body
- A Research Study Looking at How Cagrilintide Works on the Heart Rhythm in Healthy Participants
- A Research Study Looking Into Blood Levels of NNC0174-0833 in People With Normal and Impaired Kidney Function
- A Research Study Looking Into How Cagrilintide Influences Food Intake and Appetite in People With Overweight or Obesity
- A Research Study of How NNC0174-0833 Behaves in Chinese Volunteers Who Are Normal Weight, Overweight or With Obesity
- A Research Study of How NNC0174-0833 Behaves in Japanese and Caucasian Volunteers Who Are Normal Weight, Overweight or With Obesity
- A Research Study of How NNC0174-0833 Taken With Semaglutide Works in People Who Are Overweight or Obese
- A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
- A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Combined Versus Separate Injections in People With Overweight or Obesity
- A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Single Doses of Different Versions of Injectable CagriSema in Adults With Overweight or Obesity
- A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight
- A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight
- A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes
- A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy
- A Research Study to Look at How CagriSema Influences Food Intake, Appetite and Emptying of the Stomach in People With Excess Body Weight
- A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
Drugs (8)
- Adrenomedullin
- Cagrilintide
- Calcitonin
- Calcitonin human
- Calcitonin salmon
- Davalintide
- Pramlintide Amylin receptor AMY3; CALCR/RAMP3 agonist
- Pramlintide acetate Amylin receptor AMY3; CALCR/RAMP3 agonist